• The 6th annual E-Cigarette Summit will take place on Thursday 15th November 2018 at The Royal Society, London
  • The 2017 speaker videos are now available on the "Resources" page
  • The 2nd US E-Cigarette Summit will take place in Washington 30th April 2018

Key Topics

Science, regulation and public health

Smoking is the biggest single cause of preventable death in the developed world with almost 1 billion users worldwide. The devastating effect of long-term smoking cannot be underestimated, with approximately half of all lifetime smokers dying from smoking related diseases and many more suffering a compromised quality of life. Even with these known risks, traditional tobacco products remain readily available.

Despite compelling evidence that e-cigarettes represent a fraction of the harm of smoking, there have been a myriad of contradictory news headlines on the safety of e-cigarettes. As a result, the public understanding of the relative risks of vaping and smoking has deteriorated significantly. ASH (UK) found the share of respondents who described e-cigarettes as “more harmful” or “equally harmful” to tobacco cigarettes rose from about 8% in 2012 to 20% in 2014 with another 23% saying that they “did not know”. American surveys have found a similar trend.

The recent publication of  reports by Public Health England (PHE) and the Royal College of Physicians (RCP) advocated strongly for the inclusion of e-cigarettes as a reduced harm product for smokers. Both of these reports while heralded by many was controversial with other public health agencies and anti-smoking groups who maintain that the long term impact of e-cigarette on public health remains uncertain and that e-cigarettes should be considered harmful until proven safe.

This raises a far more immediate question of how “evidence” and “harm” is defined. Without consensus on these crucial points, a circular argument has emerged. Whilst it may be some time until consensus is reached on the impact of e-cigarettes on public health, should there be a moral imperative to consistently represent the relative harms of e-cigarettes to traditional tobacco products?

The E-Cigarette Summit provides a much needed neutral platform to explore the available peer reviewed evidence and debate the issues that are dividing scientists, health professionals and policy makers alike. So, are-cigarettes a valuable harm reduction strategy or a tacit U-turn on decades of effective tobacco control efforts? Whichever side of the debate you fall on, this is likely to be one of the most significant public health issues for a generation.

2016 Key Topics included:

  • Do e-cigarettes pose a health risk to non-users and should they be banned in public places
  • How safe are e-cigarettes – current clinical trials – what do we know and what do we still need to find out
  • Do e-cigarettes undermine current tobacco control measures or offer new opportunities
  • Are flavours an essential component for their attractiveness and continued use by ex-smokers or a cynical ploy to attract children
  • Evidence on Gateway, what is the available data and how should it be interpreted.
  • Use of e-cigarettes in public and work places, what should be considered before making a decision
  • How will implementation of the TPD affect the current market and products available. Intended and unintended consequences
  • Advertising and promotion, what are the issues and how will these be addressed post TPD implementation.
  • Conflicting interests that arise from the dual corporate ownership of tobacco products and harm reduction products – Is the problem ideological or a public health threat
  • How does use of e-cigarettes compare with existing nicotine replacement therapies – what should the stop smoking services and cessation practitioners be saying to current smokers?

2016 Speakers Include:

  • Prof. Ann McNeill (Chair Person) – Professor of Tobacco Addiction (UKCTAS)
  • Prof. David Abrams – Professor, The John Hopkins Bloomberg School of Public Health
  • Tom Miller – The Attorney General of Iowa
  • Professor Neal L. Benowitz – Professor of Medicine and Bioengineering & Therapeutic Sciences, University of California, San Francisco, USA
  • Deborah Arnott – Chief Executive Officer, Action on Smoking (ASH)
  • Prof David Spiegelhalter – Winton Professor for the Public Understanding of Risk, Centre for Mathematical Sciences, Cambridge University
  • Beryl Keeley – E-cigarette Notification Scheme Lead, Medicines and Healthcare Products Regulatory Agency
  • Tim Baxter – Head of Public Health Policy and Strategy Unit, Department of Health (DoH)
  • Prof Linda Bauld – Professor of Health Policy, University of Stirling and (UKCTAS)
  • Fraser Cropper – Managing Director, Totally Wicked
  • Dr Konstantinos Farsalinos – Researcher, Onassis Caridac Surgery Centre, Greece
  • Prof. Peter Hajek – Professor of Clinical Psychology, Queen Mary’s University London
  • Robert Morrison – Senior Regulatory Policy Executive – Committee of Advertising Practice
  • Prof Marcus Munafo – Professor of Biological Psychology, University of Bristol
  • Rosanna O’Connor – Director – Public Health England, Alcohol, Drugs and Tobacco
  • Prof. Ricardo Polosa – Director of the Institute for Internal Medicine and Clinical Immunology, University of Catania
  • Prof. Robert West – Professor of Health Psychology and Director of Tobacco Studies (CRUK)
  • Speaker tbc –  MHRA

To see speaker biographies please click here